| Literature DB >> 30486705 |
Hui-Chen Han1, Francis J Ha1, Andrew W Teh1,2, Paul Calafiore1, Elizabeth F Jones1, Jennifer Johns1, Anoop N Koshy1, David O'Donnell1, David L Hare1, Omar Farouque1, Han S Lim1,3.
Abstract
Background The relationship between mitral valve prolapse ( MVP ) and sudden cardiac death ( SCD ) remains controversial. In this systematic review, we evaluate the relationship between isolated MVP and SCD to better define a potential high-risk subtype. In addition, we determine whether premortem parameters could predict SCD in patients with MVP and the incidence of SCD in MVP . Methods and Results Electronic searches were conducted in PubMed and Embase for all English literature articles published between 1960 and 2018 regarding MVP and SCD or cardiac arrest. We also identified articles investigating predictors of ventricular arrhythmias or SCD and cohort studies reporting SCD outcomes in MVP . From 2180 citations, there were 79 articles describing 161 cases of MVP with SCD or cardiac arrest. The median age was 30 years and 69% of cases were female. Cardiac arrest occurred during situations of stress in 47% and was caused by ventricular fibrillation in 81%. Premature ventricular complexes on Holter monitoring (92%) were common. Most cases had bileaflet involvement (70%) with redundancy (99%) and nonsevere mitral regurgitation (83%). From 22 articles describing predictors for ventricular arrhythmias or SCD in MVP , leaflet redundancy was the only independent predictor of SCD . The incidence of SCD with MVP was estimated at 217 events per 100 000 person-years. Conclusions Isolated MVP and SCD predominantly affects young females with redundant bileaflet prolapse, with cardiac arrest usually occurring as a result of ventricular arrhythmias. To better understand the complex relationship between MVP and SCD , standardized reporting of clinical, electrophysiological, and cardiac imaging parameters with longitudinal follow-up is required.Entities:
Keywords: mitral valve; sudden cardiac death; ventricular fibrillation; ventricular tachycardia
Mesh:
Year: 2018 PMID: 30486705 PMCID: PMC6405538 DOI: 10.1161/JAHA.118.010584
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Search algorithm. MVP indicates mitral valve prolapse; SCD, sudden cardiac death.
Baseline Characteristics in Cases of MVP and SCD or Cardiac Arrest
| Baseline Characteristics | All Cases (N=161) | iMVP (n=123) | Non‐iMVP (n=38) |
|---|---|---|---|
| Age, y | |||
| Range | 6–79 | 6–79 | 8–76 |
| Mean±SD | 37±16 | 36±16 | 40±17 |
| Median (IQR) | 32 (25–51) | 30 (25–47) | 36 (26–56) |
| Female sex | 109 (68) | 85 (69) | 24 (63) |
| SCD | 100 (62) | 75 (61) | 25 (66) |
| Circumstances of death or cardiac arrest | n=98 | n=74 | n=24 |
| Sleeping | 6 (6) | 5 (7) | 1 (4) |
| Normal daily activity | 45 (46) | 34 (46) | 11 (46) |
| Exertion or soon after | 22 (22) | 17 (23) | 5 (21) |
| Emotional stress | 6 (6) | 4 (5) | 2 (8) |
| Driving | 4 (4) | 4 (5) | 0 |
| Anesthesia related | 6 (6) | 5 (7) | 1 (4) |
| Pregnancy related | 4 (4) | 3 (4) | 1 (4) |
| Witnessed in hospital | 5 (5) | 2 (3) | 3 (13) |
| Prior symptoms | n=71 | n=48 | n=23 |
| Dizziness | 14 (20) | 11 (23) | 3 (13) |
| Syncope | 25 (35) | 14 (29) | 11 (48) |
| Dyspnea | 9 (13) | 5 (10) | 4 (17) |
| Chest pain | 20 (28) | 15 (31) | 5 (22) |
| Palpitations | 39 (55) | 28 (58) | 11 (48) |
| Fatigue | 6 (8) | 4 (8) | 2 (9) |
| None | 12 (17) | 10 (21) | 2 (9) |
| Previous cardiac arrest | n=20 | n=14 | n=6 |
| Yes | 8 (40) | 3 (21) | 5 (83) |
| No | 12 (60) | 11 (79) | 1 (21) |
| Medication use | n=57 | n=32 | n=25 |
| Digoxin | 7 (13) | 1 (3) | 6 (24) |
| β‐Blocker | 16 (28) | 7 (22) | 9 (36) |
| Class 1 | 10 (18) | 0 | 10 (40) |
| Amiodarone | 1 (2) | 0 | 1 (4) |
| Other medications | 15 (26) | 9 (28) | 6 (24) |
| Nil | 17 (30) | 16 (50) | 1 (4) |
| Family history of SCD | n=28 | n=22 | n=6 |
| Yes | 4 (14) | 3 (14) | 1 (17) |
| No | 24 (86) | 19 (86) | 5 (83) |
Values are expressed as number (percentage) unless otherwise indicated. iMVP indicates isolated mitral valve prolapse; MVP, mitral valve prolapse; IQR, interquartile range; SCD, sudden cardiac death.
Includes death at home, work (nonphysical), or during commute.
One case was after sexual intercourse.
Four cases during induction, 1 case during anesthesia reversal, and 1 case during peripheral arterial puncture.
Two cases were during pregnancy, 1 case during epidural injection, 1 case (classified as nonisolated mitral valve prolapse [non‐iMVP]) was 2 days postpartum with likely tachycardia‐mediated cardiomyopathy caused by permanent junctional reciprocating tachycardia.
Multiple symptoms in some cases.
Three cases with documented ventricular fibrillation.
Two patients taking sotalol (classified as non‐iMVP).
Includes propafenone, procainamide, mexilitine, quinidine, disopyramide, and flecainide.
Includes amoxicillin, diuretics, antiepileptics, primidone, methyldopa, perindopril, trastuzumab, inhaled glucocorticosteroids, danazol, domperidone, and various psychotropic agents in 3 cases.
Figure 2Age at time of death or cardiac arrest in mitral valve prolapse according to sex.
Electrical Findings in Cases of MVP and SCD or Cardiac Arrest
| Electrical Findings | All Cases | iMVP | Non‐iMVP |
|---|---|---|---|
| Baseline ECG changes | n=81 | n=59 | n=22 |
| Inferior TWI | 15 (19) | 14 (24) | 1 (5) |
| Other ST‐T changes | 16 (20) | 11 (19) | 5 (23) |
| PVCs | 40 (49) | 30 (51) | 10 (45) |
| Normal | 23 (28) | 19 (32) | 4 (18) |
| Atrial fibrillation | 9 (11) | 5 (8) | 4 (18) |
| Left ventricular hypertrophy | 5 (6) | 2 (3) | 3 (14) |
| Other | 9 (11) | 5 (8) | 4 (18) |
| Holter findings | n=36 | n=24 | n=12 |
| No PVCs | 4 (11) | 2 (8) | 2 (17) |
| PVCs and couplets only | 20 (56) | 15 (63) | 5 (42) |
| Nonsustained VT | 10 (28) | 7 (29) | 3 (25) |
| TDP/VF | 2 (6) | 0 | 2 (17) |
| Cardiac arrest rhythm | n=72 | n=53 | n=19 |
| VF | 58 (81) | 43 (81) | 15 (79) |
| VT | 9 (13) | 6 (11) | 3 (16) |
| TDP | 3 (4) | 2 (4) | 1 (5) |
| Asystole | 2 (3) | 2 (4) | 0 |
| PVS findings | n=26 | n=22 | n=4 |
| Normal | 13 (50) | 12 (55) | 1 (25) |
| Nonsustained VT | 6 (23) | 5 (23) | 1 (25) |
| Sustained VT | 2 (8) | 1 (5) | 1 (25) |
| VF | 5 (19) | 4 (18) | 1 (25) |
| Site of origin of PVCs or VT | n=10 | n=6 | n=4 |
| Left ventricle | 3 (30) | 2 (33) | 1 (25) |
| Right ventricle | 5 (50) | 4 (67) | 1 (25) |
| Both | 2 (20) | 0 | 2 (50) |
Values are expressed as number (percentage). MVP indicates mitral valve prolapse; PVS, programmed ventricular stimulation; SCD, sudden cardiac death; TDP, torsades de pointes; VF, ventricular fibrillation; VT, ventricular tachycardia.
Multiple changes in some cases.
All leads (11 cases), lead III (1 case), leads II and III (2 cases), and leads III and aVF (1 case).
T‐wave inversion (TWI) in lateral leads (7 cases), TWI in V1–V3 (1 case), diffuse changes (1 case), and not specified (7 cases).
Includes multiple premature ventricular complexes (PVCs) (1), multifocal PVCs (6), bigeminy (3), and couplets (1).
Includes premature atrial complexes, bundle branch blocks, and accessory pathway (isolated mitral valve prolapse [iMVP] cases); Brugada pattern, prolonged QT, left axis deviation, and poor R‐wave progression (nonisolated mitral valve prolapse [non‐iMVP] cases).
Figure 3Twelve‐lead ECGs of ventricular tachycardia. Left and right bundle morphology interpretation based on V1 appearance. A, Left bundle morphology, inferior axis (isolated mitral valve prolapse [iMVP], reproduced with permission from Elsevier).23 B, Left bundle morphology, inferior axis (nonisolated iMVP [non‐iMVP], patient taking procainamide, reproduced with permission from Elsevier).24 C, Left bundle morphology, superior axis (iMVP, reproduced with permission from BMJ Publishing Group Ltd.).25 D, Right bundle morphology, superior axis (iMVP, reproduced with permission from Elsevier).26
Figure 4Documented onset of ventricular arrhythmias. A, Late diastolic premature ventricular complex (PVC)–triggered polymorphic ventricular tachycardia (VT; nonisolated mitral valve prolapse [non‐iMVP], patient taking quinidine, reproduced with permission from Elsevier)27 B, Possible PVC‐triggered polymorphic VT (isolated mitral valve prolapse [iMVP], reproduced with permission from Elsevier)28 C, Monomorphic VT with pace termination (non‐iMVP, patient taking procainamide, reproduced with permission from Elsevier)24 D, Late diastolic couplets triggering polymorphic then fast VT (non‐iMVP, patient had arrhythmogenic right ventricular cardiomyopathy, reproduced with permission from Elsevier)29 E, Late diastolic PVC–triggered polymorphic VT with varying PVC morphologies in rhythm strip (iMVP, reproduced with permission from Elsevier)30 F, (bottom 2 strips), PVC–triggered recurrent VF (iMVP, reproduced with permission from Elsevier).31
Imaging Findings in Cases of MVP and SCD or Cardiac Arrest
| Imaging Findings | All Cases | iMVP | Non‐iMVP |
|---|---|---|---|
| Leaflet involvement | n=83 | n=57 | n=26 |
| Bileaflet | 57 (69) | 40 (70) | 17 (65) |
| Posterior leaflet | 23 (28) | 15 (26) | 8 (30) |
| Anterior leaflet | 3 (4) | 2 (4) | 1 (4) |
| MR severity | n=38 | n=23 | n=15 |
| Nil/trivial | 9 (24) | 6 (26) | 3 (20) |
| Mild | 12 (32) | 9 (39) | 3 (20) |
| Moderate | 8 (21) | 4 (17) | 4 (27) |
| Severe | 9 (24) | 4 (17) | 5 (33) |
Values are expressed as number (percentage). iMVP indicates isolated mitral valve prolapse; non‐MVP, nonisolated mitral valve prolapse; MVP, mitral valve prolapse; MR, mitral regurgitation; SCD, sudden cardiac death.
Determination based on either noninvasive imaging reports and/or autopsy reports.
Cardiac Structural Findings Based on Autopsy Reports, Surgical Reports, or Cardiac Investigations
| Cardiac Structural Findings | All Cases | iMVP | Non‐iMVP |
|---|---|---|---|
| Mitral valve changes | n=88 | n=73 | n=15 |
| Redundant leaflet(s) | 87 (99) | 72 (99) | 15 (100) |
| Annulus circumference, mm | n=19 | n=15 | n=4 |
| Range | 96–160 | 100–160 | 96–135 |
| Median, IQR | 125 (100–136) | 126 (113–138) | 106 (97–120) |
| Anterior leaflet length, mm | n=15 | n=13 | n=2 |
| Range | 20–35 | 20–35 | 20–28 |
| Median, IQR | 30 (25–30) | 30 (25–30) | |
| Posterior leaflet length, mm | n=16 | n=13 | n=3 |
| Range | 15–30 | 15–30 | 15–30 |
| Median, IQR | 25 (20–30) | 25 (20–30) | 28 |
| Chordal changes | n=56 | n=45 | n=11 |
| Normal | 3 (5) | 2 (4) | 1 (9) |
| Abnormal | 37 (66) | 28 (62) | 9 (82) |
| Ruptured | 16 (29) | 15 (33) | 1 (9) |
| Left ventricle histology | n=40 | n=30 | n=10 |
| Normal | 20 (50) | 18 (60) | 2 (20) |
| Abnormal | 20 (50) | 12 (40) | 8 (80) |
| Other cardiac abnormalities | n=50 | n=27 | n=23 |
| Left ventricular hypertrophy or cardiomegaly | 14 (28) | 0 | 14 (61) |
| Right ventricular fibrosis | 6 (12) | 5 (19) | 1 (4) |
| Coronary artery disease | 6 (12) | 0 | 6 (26) |
| Other | 6 (12) | 5 (19) | 1 (4) |
| Nil | 18 (36) | 17 (63) | 1 (4) |
IQR indicates interquartile range.
Includes descriptive terms myxomatous, ballooned, thickened, nodose, hooding, floppy, voluminous, opaque, and edematous.
Three additional cases reported a dilated annulus without measurement.
Descriptions included elongated, thickened, and/or fused.
Fifteen normal samples were from 1 series (all samples in that series were normal).11
Heterogeneous group of descriptors including fibrosis affecting the interventricular septum (3), interstitial fibrosis (5), extensive papillary muscle fibrosis (1), slight papillary muscle fibrosis (2), subendocardial fibrosis affecting the papillary muscles (2), presence of myxomatous material within the papillary muscles (1), multifocal necrosis (3), high‐grade left ventricular hypertrophy changes (1), and degenerated elastic fibers (1).
One case with arrhythmogenic right ventricular cardiomyopathy (nonisolated mitral valve prolapse [non‐iMVP]).
Includes left main coronary disease (1), anomalous right coronary artery (2), coronary vasospasm (1), prior inferior infarct (1), and significant diffuse coronary disease in the setting of pseudoxanthoma elasticum (1).
Includes tricuspid valve prolapse (3) and previous endocarditis (2) (isolated mitral valve prolapse cases) and significant conduction system fibrosis (1) (non‐iMVP case).
Predictors of VAs or SCD
| Author | Year | Study population | Predictor/association | Outcome/Endpoint |
|---|---|---|---|---|
| Clinical | ||||
| Gaffney39 | 1979 | MVP |
Higher heart rate | Clinical severity (combination of symptoms and VAs) |
| Puddu40 | 1983 | MVP | Plasma catecholamine level | QTc |
| Sniezek41 | 1992 | MVP | Adrenaline excretion | Complex VAs (Lown grade ≥3) |
| Zuppiroli42 | 1994 | MVP | Female | Complex VAs (Lown grade ≥3) |
| Babuty43 | 1994 | MVP | Age (older) | Complex VAs (Lown grade ≥3) |
| Naksuk44 | 2016 | MV surgery | Age (younger) | PVC reduction post‐surgery in BiMVP |
| Fulton45 | 2017 | MVP | Female | PVCs from PM |
| Electrical | ||||
| Campbell46 | 1976 | MVP | Inferolateral T‐wave changes | VT (>100bpm for ≥3 beats) or VF |
| Babuty43 | 1994 | MVP | Late potentials | VT (≥3 beats) |
| Bobkowski47 | 2002 | MVP | Late potentials | VAs (Lown grade ≥1) and VT (>120bpm for ≥4 beats) |
| Akcay48 | 2010 | MVP | QTc dispersion | VT (>120bpm for ≥3 beats) |
| Imaging | ||||
| Shah49 | 1982 | MVP | MR | Complex VAs (Lown grade ≥3) |
| Nishimura18 | 1985 | MVP | Redundant leaflets | Sudden death |
| Kligfield5 | 1985 | MVP | MR | VAs (>1% PVC frequency or exercise induced PVCs/VT or Lown grade ≥4 complex VAs) |
| Sanfilippo50 | 1989 | MVP |
Anterior leaflet thickness | VAs (≥10 PVCs/hr or VT at ≥100bpm for ≥3 beats) |
| Zuppiroli42 | 1994 | MVP | Anterior leaflet thickness | Complex VAs (Lown grade ≥3) |
| Babuty43 | 1994 | MVP | MR | Complex VAs (Lown grade ≥3) |
| Zouridakis51 | 2001 | MVP |
MVP degree | QT dispersion |
| Turker52 | 2010 | MVP | Moderate‐severe MR | VAs (Lown grade ≥1) |
| Carmo53 | 2010 | MVP | Mitral annular disjunction | Non‐sustained VT (NS) |
| Han54 | 2010 | MVP | LGE in PM | Complex VAs (Lown grade ≥4) |
| Akcay48 | 2010 | MVP | Anterior leaflet length | VT (>120 bpm for ≥3 beats) |
| Sriram3 | 2013 | OHCA | BiMVP | Appropriate ICD therapies at follow‐up |
| Basso4 | 2015 | MVP | LGE | Complex VAs (Lown grade ≥4b or VF) |
| Nordhues55 | 2016 | MVP | BiMVP | All‐cause mortality |
| Bui56 | 2017 | MVP | Myocardial T1 time | Complex VAs (Lown grade ≥3) |
| Fulton45 | 2017 | MVP |
BiMVP | PVCs from PM |
BiMVP indicates bileaflet mitral valve prolapse; bpm, beats per minute; ICD, implantable cardioverter‐defibrillator; LGE, late‐gadolinium enhancement; MR, mitral regurgitation; MV, mitral valve; MVP, mitral valve prolapse; OHCA, out‐of‐hospital cardiac arrest; NS, not specified; PM, papillary muscle; PVCs, premature ventricular complexes; QTc, corrected QT; SCD, sudden cardiac death; VAs, ventricular arrhythmias; VF, ventricular fibrillation; VT, ventricular tachycardia.
Significant result on multivariate analysis; significant univariable predictors are not presented.
Prospective Follow‐Up Studies in MVP With SCD Rates
| Study Author | Patients, No. | Mean Age, y | Females, No. | Mean Follow‐Up, y | SCD Events/100 000 Patient‐Y, No. |
|---|---|---|---|---|---|
| Nishimura | 237 | 44 | 142 | 6.2 | 408 |
| Düren | 300 | 42 | 164 | 6.2 | 219 |
| Zuppiroli | 316 | 42 | 220 | 8.5 | 112 |
MVP indicates mitral valve prolapse.
A total of 97 patients had redundant leaflets—all cases of sudden cardiac death (SCD) occurred in those with redundant leaflets.
Figure 5Sudden cardiac death (SCD) incidence in mitral valve prolapse (MVP) versus population studies.